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1. Abstract 
Polycaprolactone (PCL) matrices incorporating lactoferrin as a natural 
macromolecular microbicide, were prepared by rapidly cooling a suspension of 
lactoferrin particulates in PCL solution to induce crystallisation and hardening 
of the polymer. Thermal analysis revealed a 7% decrease in crystallinity of the 
PCL phase for 10% lactoferrin-loaded matrices compared with lactoferrin-free 
matrices and a 41% decrease in hardness of lactoferrin -loaded matrices, 
indicating a major influence of lactoferrin through inhibition of PCL crystal 
nucleation and growth. Exposure of the matrices to simulated vaginal fluid 
(SVF) at 37°C resulted in rapid release of 13-14% of the lactoferrin content on 
day 1 and sustained delivery of the glycoprotein with high efficiency (90-95% 
of the content) over 14 days. SDS-PAGE analysis confirmed molecular weight 
preservation of the lactoferrin released from PCL matrices into SVF, indicating 
that it was not degraded during formulation and release.  These findings 
recommend further investigations of PCL matrices as vaginal delivery systems 
for controlled release of macromolecular microbicides in the treatment and 
prevention of sexually transmitted infections. 
2. Introduction 
Vaginal drug delivery systems exist in a variety of forms including semi solids 
(gels and creams), tablets, films and ring-shaped inserts. Intravaginal rings 
(IVRs) were initially developed for contraceptive purposes and hormone 
replacement therapy and offer advantages over semi-solid formulations, 
including ease of insertion, avoidance of ‘messiness’ and long term, sustained 
drug delivery (1). More recently, IVRs have become the subject of intensive 
research for sustained delivery of small molecule microbicides that are effective 
against sexually transmitted infections (STIs) (2), including the non-nucleoside 
reverse transcriptase inhibitor (NNRTI) dapivirine (3) that inhibits HIV/AIDS 
transmission. Recent phase 3 clinical trials evaluating the safety and efficacy of 
an extended use vaginal ring containing dapivirine revealed that the incidence 
of HIV-1 infection was 31% lower (4) and 27% lower (5) in the dapivirine 
group than in the placebo group. 
 
 
IVRs offer advantages of targeted drug delivery at the point of entry of 
pathogens implicated in STIs and direct contact of the drug with infected cells. 
However, many of the newer biotech-derived microbicides under development 
for the treatment and prevention of STIs are macromolecular in nature and 
require new strategies to enhance the efficiency of vaginal delivery (6-8). 
Several monoclonal antibodies (mAbs) including enfuvirtide, have been 
reported to protect macaques from challenge with the simian/human 
immunodeficiency virus (SHIV) via IV, oral, rectal and vaginal routes. The 
mAbs were also found to be active against a wide variety of HIV isolates, thus 
offering major potential for controlling transmission (8). The HIV-1 envelope 
glycoprotein, CN54gp140, was formulated as a liposome gel to produce a 
vaccine against HIV-1 infection (9). Although an encapsulation efficiency of 
35% was reported and the glycoprotein maintained antigenic activity above 
80%, insertion and retention of the gel, coupled with the likelihood of 
inefficient exposure of the antigen to the host to induce an immune response 
remain a problem.  
Silicone elastomer and polyethylene vinyl acetate (pEVA) are conventionally 
employed for manufacturing IVRs for delivery of small molecule therapeutics 
such as contraceptive steroids (10), but these polymers are almost impermeable 
to macromolecular drugs. In addition, curing of silicone elastomer is carried out 
at temperatures above 80oC and pEVA is typically moulded at 140oC, which 
raises concerns over thermal degradation of peptide/protein-based therapeutics. 
Consequently, IVRs which are designed for delivery of macromolecular entities 
commonly include the active in an integral pod or insert, which complicates 
manufacture of the device (11-13). Bovine serum albumin (BSA) (employed as 
a protein antigen) was incorporated in silicone elastomer IVRs in the form of an 
insert. Around 80% of the protein was released over a 12-week period in vitro 
and exhibited good protein stability (11). Similarly, a 10-pod insert IVR 
sustained release of antibody IgG in vitro at a level of 0.5-30 mg/day for 14 
days with retained activity according to ELISA testing (12). A ‘rod-insert’ type 
vaginal ring for delivery of the anti-retroviral peptides T-1249 and 
JNJ54310516-AFP, has recently attracted interest (13). The broadly neutralising 
antibody VRCO1-N was included in pod-type IVRs for evaluation of 
pharmacokinetics and safety in macaques (6). Antibody release was sustained 
for up to 21 days resulting in levels in vaginal fluid in the range 102-103 µg g-1 
with no adverse safety indications. Although, designs such as these can provide 
alternative solutions to the delivery of challenging molecules their complex 
design increases the cost of manufacture of the device.  
Microporous polycaprolactone (PCL) matrices loaded with a bioactive 
compound can be produced without the use of high temperatures. Rapid cooling 
of bioactive particle suspensions in PCL solution has been investigated for 
intravaginal delivery of small molecule antiviral, antibacterial, antifungal and 
antiprotozoal drugs (14-17). PCL matrices have also been shown to be effective 
for sustaining release of gelatin in vitro as a model macromolecular 
biopharmaceutical (18). PCL matrices containing gelatin particles of size range 
90–125 and 125–250 mm, respectively, displayed gradual and highly efficient 
release of around 90% of the protein phase in PBS over 21 days. Micro-CT 
analysis revealed formation of a highly macroporous structure following protein 
extraction (18). Enzymes have also been successfully loaded and released from 
PCL matrices, with activity shown to be retained at 100% for at least 11 days 
for collagenase (19). Lysozyme activity was 75–80% at 11 days, but catalase 
reduced to 10–20% at 5 days. The study indicated the potential of microporous 
PCL matrices for delivering bioactive protein and peptide macromolecules. 
Lactoferrin is an 80 kDa iron-binding glycoprotein of the transferrin family that 
is expressed in most biological fluids including mucosal secretions (vaginal, 
nasal, bronchial, intestinal), milk and colostrum (20, 21). Lactoferrin is a major 
component of the mammalian innate immune system and displays anti-oxidant, 
anti-inflammatory and anti-cancer activity. In particular, it has demonstrated 
microbicidal activity against a wide range of microorganisms implicated in 
sexually transmitted infection (22-25). The glycoprotein is bacteriostatic against 
iron-dependent bacteria due to its iron-binding property, which depletes the 
concentration of iron and consequently bacterial growth at sites of infection (22, 
23). Antibacterial activity against gram-negative bacteria stems from 
electrostatic binding of lactoferrin’s positive N-terminus with anionic moieties 
on lipopolysaccharide (LPS) resulting in deleterious changes in cell membrane 
permeability (24,25). Anti-fungal activity against Candida albicans is also 
considered to occur by direct interaction, resulting in altered permeability of the 
cell wall (22).  Lactoferrin exerts antiviral activity in vitro by inhibiting HIV 
replication within infected cells (23) and by blocking entry of herpes simplex 
virus into host cells by binding to the virus particle or the glycosaminoglycan 
viral receptors on host cells (24). Sessa et al recently reported that lactoferrin 
could both interfere with Chlamydia trachomatis entry into epithelial cells in 
vitro and exert anti-inflammatory activity (25). Of particular note was the 
authors’ demonstration of a protective effect of lactoferrin against C. 
trachomatis infection in vivo, as evidenced by six out of seven pregnant women, 
who were asymptomatically infected by C. trachomatis, being negative 
for C. trachomatis after 30 days intravaginal administration of lactoferrin. 
The mounting evidence in support of lactoferrin in a preventative and 
therapeutic role against a wide range of microrganisms stimulated the current 
evaluation of PCL matrices for sustained vaginal delivery of the glycoprotein as 
a natural macromolecular microbicide in the treatment of STIs. 
3. Materials and methods 
3.1 Materials 
Polycaprolactone (PCL, MW 115,000 Da, Capa 650) was obtained from Solvay 
Interox (Warrington, UK). Bovine lactoferrin, native form (26) (from MG 
Nutritionals) was a gift from Dr. Nidhi Bansal (Lecturer, School of Agriculture 
and Food Science, University of Queensland).  Sodium chloride, potassium 
hydroxide, calcium chloride, bovine serum albumin, glucose, glycerol, urea, 
lactic acid and acetic acid were purchased from Sigma-Aldrich (Castle Hill, 
NSW, Australia). Solvents (acetone, acetonitrile) were of analytical grade and 
purchased from Sigma-Aldrich, Australia. 2X Laemmli sample buffer, 12% 
SDS precast, 15 well gels were purchased from Bio-Rad (Gladesville, NSW, 
Australia). PageRuler plus pre-stained protein ladder was purchased from 
ThermoFisher Scientific (Scoresby, Vic, Australia). 
 
3.2 Production of lactoferrin-loaded PCL matrices 
Cylindrical PCL matrices loaded with lactoferrin were prepared according to a 
previously reported method (14). PCL pellets (1.5g) were dissolved in 10 mL 
acetone to produce a 15% w/v solution, by heating at 45°C for 45 min. 
Lactoferrin powder was dispersed in the PCL solution to produce protein 
loadings of 5% and 10% w/w with respect to the PCL content. The resulting 
suspension was poured into 3 mL polypropylene syringe barrels and cooled 
rapidly by immersion in methanol at -80oC to cause crystallisation and 
hardening of PCL. After retention at -80oC for 24 h the resulting lactoferrin-
loaded PCL matrices were removed from the moulds and dried for 24 h under 
ambient conditions to evaporate solvent. The final matrices were in the form of 
cylinders of diameter 6.3 ± 0.2 mm and length 45.0 ± 3.0 mm.  
3.3 Matrix morphology 
The morphology of lactoferrin-loaded PCL samples was examined using a 
JEOL-6610LV scanning electron microscope (SEM) (Jeol Ltd., Tokyo, Japan). 
Samples were taken from the surface and interior of PCL matrices and attached 
to aluminium stubs prior to coating using an Eiko sputter coater automatic 
mounting press. Coated samples were imaged using an applied voltage of 10 
kV.  
3.4 Thermal analysis 
Differential scanning calorimetry (DSC) (1 STARe DSC System, Mettler-
Toledo Ltd., Victoria, Australia) was used to measure the glass transition 
temperature (Tg) and crystallinity of the PCL matrices. Samples of lactoferrin-
free matrices and samples loaded with lactoferrin, respectively, were weighed 
and sealed in aluminium pans and heated over the temperature range 30-330°C 
at a rate of 10°C/min. The Tg and crystallinity of the PCL phase were obtained 
using the DSC software facility.  The percentage crystallinity of the PCL phase 
was estimated using a heat of fusion of 139.5 J/g for the fully crystalline 
polymer (27).  
3.5 Hardness testing of matrices 
Values of hardness for lactoferrin-free matrices and lactoferrin-loaded matrices 
were obtained using a CT3 Texture Analyzer (Brookfield Engineering 
Laboratories Inc., Middleboro, MA). Cylindrical PCL mouldings were mounted 
horizontally and compressed locally at a speed of 0.1 mm/min to a depth of 2.0 
mm using a 2.0 mm diameter, flat-ended, cylindrical probe (TA39). The 
hardness (or indentation resistance) of each sample was calculated based on the 
applied force measured at a depth of penetration of 2 mm. A pEVA IVR 
(Nuvaring®, Schering-Plough Pty limited, New South Wales, Australia) was 
subjected to the same test procedure for comparison. 
3.6 In vitro release of lactoferrin from PCL matrices  
The release behaviour of lactoferrin-loaded PCL matrices was investigated by 
immersing samples in simulated vaginal fluid (SVF) as the release medium. The 
ends of cylindrical mouldings were sealed using 5% w/v PCL solution to 
confine release of lactoferrin to the cylinder surface and thus mimic the release 
behaviour of an IVR. Samples were immersed in 10 mL of SVF and retained in 
an incubator at 37°C for 14 days. The volume of SVF was based on the 
maximum volume of vaginal fluid produced by healthy, non-pregnant, pre-
menopausal women in one day (28). SVF was produced using the method 
reported by Owen and Katz (28) and contained 3.51g NaCl, 1.40g KOH, 0.222g 
Ca(OH)2, 0.018g bovine serum albumin, 2.00g lactic acid, 1.00g acetic acid, 
0.16g glycerol, 0.4g urea and 5.0g glucose in 1L of distilled water. The pH was 
adjusted to 4.2 using 10% HCl to simulate the pH condition of vaginal fluid. 
The complete release medium was collected daily and replaced with 10 mL 
SVF. Release samples were stored at -18°C prior to testing. The concentration 
of lactoferrin in the collected medium was analyzed using a Shimadzu HPLC 
system equipped with binary pump and SPD-M20A photodiode array detector. 
Separation was carried out using an Agilent Extend C-18 column (2.1 x 150 
mm, 5 µm). Two mobile phases were used, water (eluent A) and 95% 
acetonitrile (eluent B), both with 0.1% (v/v) trifluoroacetic acid added. 
Time (min) %Solvent A %Solvent B 
0-15  85-30 15-70 
15-20 30 70 
20-30 30-85 70-15 
  
Gradient elution was used, with eluent B starting at 15%, increasing to 70% at 
15 minutes and holding for 5 minutes. The sample injection volume was 50 µl 
and quantification of lactoferrin was performed at 276 nm by comparison with a 
standard curve (concentration range 10-60 µg/ml (R2 = 0.9988)). Each 
experiment was performed in triplicate.  
3.7 SDS-PAGE analysis of lactoferrin released from PCL matrices 
PCL matrices loaded with 5% and 10% w/w lactoferrin and incubated in SVF 
(10mL) at 37°C for 14 days. The incubation media were collected and analysed 
using SDS-PAGE to determine the structural stability (based on molecular 
weight) of lactoferrin released from the matrices over this time scale. Aliquots 
(5 µL) of the release media containing lactoferrin were mixed with 5 µL of 
sample buffer (4.5 µL of 2x Laemmli sample buffer and 0.5 µL of beta 
mercaptoethanol). Aliquots of the mixture (5 µL) were added to separate wells 
in a 12% SDS-PAGE gel and electrophoresis was performed according to 
Laemmli (29). 
3.8 Statistics 
Significant differences between the thermal properties and hardness of the 
matrices were evaluated using one-way ANOVA with a Tukey multiple 
comparisons test (p<0.05). 
 
4. Results and discussion 
4.1 Production and morphology of the PCL matrices 
PCL matrices containing lactoferrin were produced successfully by rapidly 
cooling suspensions of lactoferrin particles dispersed in PCL solution in 
acetone. Cooling of the suspension at -80oC resulted in rapid crystallisation of 
the PCL phase, which counteracted sedimentation of the Lf particles. Previous 
investigations of the rapid cooling technique revealed a uniform dispersion of 
protein particles in the resulting PCL matrix (18). The LF-loaded PCL matrices 
could be produced in the form of IVRs, for example, by solvent bonding or 
thermal bonding of rods or by direct moulding to shape in suitably constructed 
moulds. The matrix production method involving crystallisation of polymer 
solutions, solvent evaporation and drying is time consuming and 
disadvantageous for production scale up. However, its simplicity and low cost 
lends itself to development of insertable, vaginal delivery systems for 
macromolecular actives for a range of clinical applications including vaccines 
and cervical cancer.   
The Lf-loaded matrices exhibited a microporous morphology featuring 
interconnected pores and channels. The pore size in the case of blank PCL 
matrices ranged from 3-5 µm (Figure 1a) and increased to 6-10 µm when 
lactoferrin was incorporated (Fig 1b). The lactoferrin powder used for matrix 
formation was made up of particulates ranging in size from 0.5-3 µm (Figure 
1c). Traces of lactoferrin particles were in evidence on the matrix surface (Fig 
1b, arrowed). 
    
       
                 a                                          b                                          c 
Figure 1: Scanning electron micrographs of a) interior of blank PCL matrix, b) 
interior of PCL matrix loaded with 5% w/w lactoferrin, and c) lactoferrin 
particles    
4.2 Thermal behaviour and hardness of matrices 
A reduction in crystallinity of around 7% occurred when lactoferrin was 
incorporated in PCL matrices at a level of 10% w/w but there was no 
statistically significant difference between 0, 5, and 10% loading. (Table 1). The 
reduction in crystallinity suggests that the lactoferrin particles are inhibiting 
PCL nucleation and crystal growth. Similar effects were recorded previously for 
doxycycline which caused a decrease in crystallinity of PCL matrices of around 
5% on increasing the drug concentration from 5% to 15% w/w (14). The glass 
transition temperature (Tg) of PCL was found to increase by approximately 
10oC on inclusion of lactoferrin particles in the PCL matrix (Table 1) indicating 
that the polymer chain mobility was restricted by the presence of lactoferrin, 
possibly due to adhesion between PCL chains and the lactoferrin particle 
surface.  
The reinforcing effect of particulate fillers on polymers and elastomers is well 
known, resulting in increases of strength, stiffness (or modulus) and hardness 
with increasing content or volume fraction of the filler. We have previously 
reported increased hardness of PCL matrices following inclusion of the small 
molecule antiviral, tenofovir (15), and the antibacterial, doxycycline (14), but a 
decrease in hardness for metronidazole (30). In the present study, the hardness 
of PCL matrices (1380 mN/mm2) decreased significantly to 810 mN/mm2 when 
lactoferrin particulates were incorporated (Table 1), which is much lower than 
the value measured for Nuvaring® pEVA IVR (9280 mN/mm2).   Intravaginal 
devices produced from lactoferrin-loaded matrices would thus be expected to 
increase user acceptance on insertion and residence in the vagina and to reduce 
the risk of irritation and subsequent inflammation of the vaginal epithelia.  
However, investigations of the flexural properties of Lf-loaded PCL matrices in 
the form of IVRs are essential to provide supporting information for an 
assessment of insertion and retention characteristics.   
Particulate reinforcement theory is based on the condition of inextensible or 
non-deformable particulates (31), which may be considered to be met in the 
case of inorganic small molecule, crystalline microbicides such as tenofovir and 
doxycycline. However, biopolymers including lactoferrin are commonly classed 
as low stiffness, extensible materials and their reinforcing effect on a PCL 
matrix, of similar mechanical characteristics, would be expected to be 
negligible.  Instead, the substantial softening (41%) of lactoferrin-loaded 
matrices, indicates that the glycoprotein particulates exert a major influence 
through their inhibition of PCL crystal nucleation and growth. 
Table 1: Thermal properties and hardness of PCL matrices incorporating 
lactoferrin. Mean ± standard error of three replicate experiments are given; 
values within a column sharing the same superscript letter are not significantly 
different (p<0.05). 
Lactoferrin 
loading (%w/w) 
Glass transition 
temperature (°C) 
Crystallinity 
(%) 
Hardness  
(mN/mm2) 
          0        -66.5 ± 1.2a 82.3 ± 2.3a 1382 ± 132a 
          5       -55.2 ± 0.8b 82.1 ± 4.6a 1097 ± 87b 
         10        -55.9 ± 0.9b 76.7 ± 3.3a 810 ± 62c       
 
4.3 In vitro release of lactoferrin from PCL matrices  
Rapid release of around 14% of the lactoferrin content occurred from both 5% 
and 10% loaded PCL matrices during the first 24 h of exposure to SVF (Figure 
2a). Thereafter, lactoferrin was gradually liberated from the matrices, resulting 
in highly efficient release of 90-95% of the lactoferrin content over the 14-day 
test period. The higher release observed for the 10% lactoferrin-loaded matrices 
reflects the diffusion-controlled release mechanism which predominates in 
matrix-type drug delivery systems comprised of a dispersion of drug particles in 
a polymer matrix (32, 33). Drug diffusion from the matrix is controlled in major 
part by the concentration gradient between the matrix and surrounding fluid. 
Gradual release of lactoferrin macromolecules is expected through fluid-filled, 
interconnected pores and channels in the microporous PCL matrix and may be 
facilitated by micro-cracking effects in the 10% lactoferrin-loaded material 
caused by the higher concentration of lactoferrin particulates (19). 
Chlamydia trachomatis is responsible for the most common STI and may lead 
to severe health problems including pelvic inflammatory disease and ectopic 
pregnancy (25). Sessa et al found that pre-incubation of human epithelial cells 
(HeLa-229) with lactoferrin at a concentration of 100µg/mL prior to infection 
with C. trachomatis or the addition of lactoferrin to C. trachomatis at the 
moment of infection, strongly inhibited bacteria uptake into host cells (25). In 
the present study, the minimum weight of lactoferrin released per day from 
cylindrical matrix samples into SVF (10 mL) was measured as 750µg. (Figure 
3), resulting in a concentration of 75µg/mL. The cylindrical test samples used in 
this study (45mm length) correspond to approximately one third the linear 
length of an IVR and the turnover rate of vaginal fluid is approximately 8 
mL/day (28). Therefore, the concentration of lactoferrin produced in vaginal 
fluid in vivo by a PCL matrix in the form of an IVR, may be expected to exceed, 
by a factor of 2 the lactoferrin concentration of 100µg/mL which was found by 
Sessa et al. to inhibit C. trachomatis entry into human mucosal epithelial cells 
in vitro. This basic modelling approach neglects the changes in volume and 
biochemistry of vaginal fluid over time (for example, pH), which may influence 
lactoferrin release kinetics and local concentration, but the example illustrates 
the potential of PCL matrices for maintaining high levels of lactoferrin in 
vaginal fluid at protective concentrations over extended periods of time.  
 
 
  
Figure 2: Cumulative release of lactoferrin (a) and weight of lactoferrin released 
daily (b) from PCL matrices into SVF at 37°C. PCL matrices contained 5 or 
10% w/w lactoferrin. Values are the mean ± standard error of three replicate 
experiments. 
A clinical study by Sessa et al (25) also revealed that prolonged intravaginal 
delivery of lyophilised lactoferrin over 30 days as a fast dissolving tablet 
formulation (100 mg every 8h) results in a protective effect against infection by 
C. trachomatis, in that six out of seven pregnant women asymptomatically 
infected with the bacteria, tested negative after the 30-day treatment. 
Intravaginal insertion was carried out three times a day, which may have been 
necessitated by a high leakage rate of dissolved lactoferrin. Lf-loaded PCL 
matrices offer opportunities for replacing the multiple dosing regimen by a 
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single administration, sustained delivery formulation, resulting in increased 
convenience, lower dosing and improved compliance.  
We have previously formulated sustained-release PCL matrices loaded with 
drug combinations for in vitro assessment of their anti-viral activity (tenofovir 
and nevirapine) against HIV (15) and their anti-bacterial activity (metronidazole 
and doxycycline) against pelvic inflammatory disease (34). Lactoferrin has 
demonstrated synergy against HIV when combined with the anti-viral AZT 
analogue, zidovudine (23) and has been reported to reduce the minimum 
inhibitory concentration of anti-fungal drugs including clotrimazole and 
fluconazole against C. albicans (35).  Thus, an investigation of intravaginal 
PCL matrices loaded with a combination of macromolecular and small molecule 
microbicides presents a logical and potentially useful progression of the current 
study.  
4.4 SDS-PAGE analysis 
Lactoferrin is an 80 kDa iron-binding glycoprotein of the transferrin family that 
is expressed in most biological fluids. SDS-PAGE analysis revealed that 
lactoferrin maintained its molecular size during matrix production and release 
into SVF over 14 days. The major protein band of lactoferrin at 80kDa was 
observed for the lactoferrin standard and for lactoferrin released from PCL 
matrices (Figure 3) together with a minor band at approximately 14 kDa which 
is assigned to α-lactalbumin (36). No additional bands were detected, indicating 
an absence of protein degradation. However, further studies are required to 
confirm preservation of the protein 3-D structure and the bioactivity of 
lactoferrin released from PCL matrices.The antibacterial activity of lactoferrin 
decreased by 96% against C. sakazakii during heat treatment at 72°C for 15 min 
and 85°C for 10 min (37), while heat treatment above 85oC adversely affected 
the antibacterial activity of bovine lactoferrin against the food-borne bacteria 
Escherichia coli, Salmonella enteritidis and Listeria monocytogenes (38).  Thus, 
the avoidance of high temperatures during PCL matrix formulation provides a 
decided advantage when incorporating macromolecular microbicides. 
Furthermore, lysozyme and collagenase have been successfully incorporated 
into PCL matrices and released into PBS over 11 days with retained activity in 
excess of 75% of the non-formulated enzymes (18). Thus, lactoferrin activity is 
expected to be retained when loaded and released from PCL matrices using the 
method described herein. 
           
Figure 3: SDS-PAGE analysis of lactoferrin (80 kDa): Lane 1) Molecular 
weight biomarker ladder. Lane 2) lactoferrin standard. Lane 3) Lactoferrin 
released from 5% w/w-loaded PCL matrix and Lane 4) Lactoferrin released 
from 10% w/w –loaded PCL matrix into simulated vaginal fluid at 37oC over 14 
days. 
5. Conclusion 
Lactoferrin was incorporated successfully in PCL matrices by rapidly cooling 
dispersions of lactoferrin particulates in PCL solution. Highly efficient delivery 
of 90-95% of the lactoferrin content occurred over 14 days in SVF. Lactoferrin 
was released from the matrices over 14 days without affecting glycoprotein 
integrity on the basis of SDS-PAGE analysis of molecular weight. These 
findings recommend further investigations of PCL matrices for vaginal delivery 
of lactoferrin and other macromolecular microbicides, either alone or in 
combination with conventional small molecule drugs, for the treatment and 
prevention of STIs. 
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